nartograstim and Leukemia--Myeloid--Acute

We tested the in vitro effect of a novel granulocyte colony-stimulating factor (G-CSF) derivative (KW-2228) on the growth of G-CSF-dependent hemopoietic progenitor cells: granulocyte precursor cells (CFU-G), leukemic blast progenitors freshly obtained from 9 patients with acute myeloblastic leukemia (AML) and cells of a G-CSF-dependent human AML cell line (OCI/AML 1a). KW-2228 showed a higher stimulating effect than recombinant human G-CSF (rhCSF) on CFU-G; 3 out of 9 leukemic blast progenitors and OCI/AML 1a cells. The difference in biochemical stability between rhG-CSF and KW-2228 was considered to explain the superior colony-stimulating activity of KW-2228. The results show that KW-2228 will be a new granulopoietic factor.

Topics: Amino Acid Sequence; Bone Marrow Cells; Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Molecular Sequence Data; Recombinant Proteins; Stimulation, Chemical; Structure-Activity Relationship; Time Factors; Tumor Cells, Cultured